Alchemab is a biotechnology company that develops antibody therapeutics. The company focuses on advancing novel antibodies with potential applications in various diseases, including Parkinson's disease.

Alchemab

Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of hard-to-treat disease in a unique and transformative approach to drug discovery and development. 
Alchemab takes an unbiased and function-first approach using three complementary processes and cutting-edge technologies to identify naturally protective antibodies.
Alchemab’s engine is enabled through collaborations with patient representative groups and biobanks around the world with whom we partner to further our understanding of disease.

Michael J. Fox Foundation

Biomedical Catalyst Fund

DCVC Bio

Dementia Discovery Fund

Lightstone Ventures

RA Capital Management

SV Health Investors

DHVC

DCVC

Alchemab Therapeutics Ltd

Principal Scientist at #Alchemab, Helen Graves, is presenting at the One Nucleus Innovation Seminar in Cambridge on the 'Challenges and Opportunities in Therapeutic Antibody Development'! Don't miss Helen's presentation on 5 September at 16:40pm BST, titled 'Antibodies From Resilient Individuals: A Novel Approach for Antibody Drug Discovery'.
 
Sign up to attend if you haven't already!
 
#biotech #lifesciences #antibodies #neuroscience

#Alchemab is proud to highlight that 15 team members will be taking part in the 3 Peaks Walk in Derbyshire to fundraise for our charity of the year, Age UK!
 
 The team will be heading to Derbyshire to complete 20 miles of hiking across the three highest points in the Peak District National Park on 21st September.
 
We wish them the best of luck on their walk as they continue to fundraise vital funds towards supporting Age UK in Cambridgeshire & Peterborough, who provide various services for older people and their carers.
 
 If you would like to donate to enable #AgeUK to continue their incredible work, please use the link here! https://lnkd.in/gJ4if8Vy

Thank you to everyone who has already donated for this important cause and good luck to the team!
 
#biotech #lifesciences #Cambridgeshire #Peterborough

In case you missed it, #Alchemab was featured in Drug Discovery World’s insightful report: 'Neuroscience: Advances in research and opportunities ahead', highlighting our 'patient-centric approach'! 💡

📰 Download the free report to read more about our unique approach to #drugdiscovery and our program, ATLX-1088, a CD33 inhibitor which 'offers a promising and novel therapeutic approach for the treatment of Alzheimer's disease'.

https://lnkd.in/eCEEdBCu

#biotech #lifesciences #antibodies #neuroscience #alzheimers

Alchemab is supporting The Boston Home as its US charity partner for 2024. Find out more about how Alchemab contributes to this charity's important work to support healthy aging in the article below.  
#healthyaging  #neurology #partnershipsmatter

Alchemab staff are proud to volunteer their time, raising money and awareness for charities aligned with our values and scientific focus. Today we announced that we have selected Age UK Cambridgeshire and Peterborough as our UK Charity for 2024. Read on to learn why we look forward to working with Age UK.

Alchemab Therapeutics Ltd are delighted to share that its paper titled 'A generative foundation model for antibody sequence understanding' has been accepted for two workshops at the 41st [ICML] Int'l Conference on Machine Learning in Vienna, Austria.
 
This paper introduces FAbCon, a generative antibody-specific language model comprising 2.4 billion parameters and will be presented as a poster at the workshops on Machine Learning for Life and Material Science (ML4LMS) on July 26th, and Accessible and Efficient Foundation Models for Biological Discovery (AccML) on July 27th.
 
To read our paper or download our models, use the links in the comments below!

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

logo

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Sep 4, 2024 5:58 AM	e23d83d5
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 4, 2024 10:36 AM	2dd4356f
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
peers	general	Sep 4, 2024 5:58 AM	3479c585
news basic	general	Sep 4, 2024 5:58 AM	68d1f845
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
logo	meta
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:ALCHEMAB

Alchemab